News

Enlarge image

ResearchUK

Key to herbicide resistance

26.03.2013 - British researchers have found that one single protein seems to control resistance against multiple herbicides of cereal crops weeds.

Multiple-herbicide resistance (MHR) in black-grass and annual rye-grass is a global threat for agriculture, leading to loss of chemical weed control in cereal crops. Until now, it was only poorly understood why MHR is associated with an enhanced ability to detoxify xenobiotics. Assuming an analogy with multiple drug resistance, which occurs in human tumours, researchers from York University and Syngenta now report they have found a possible explanation.

When they searched in black-grass and annual rye-grass for a plant homologue to the MDR causing phi glutathione S transferase (GSTP1) they found an enzyme that also showed both detoxification and signalling. When expressed in Arabidopsis thaliana, the protein termed GSTF1 led to multiple herbicide resistance in the model organism and showed a similar secondary metabolism pattern as the weeds. Those were not associated with a differential gene expression pattern but directly caused by GSTF1.

When they applied the GSTP1 blocker 4-chloro-7-nitro-benzoxadiazole to the weeds, the MHR masterswitch was blocked. They conclude that overexpression of GSTF1 orchestrates multi-herbicide resistance in grass weeds and that targeting the protein is a promising approach to regain weed control in cereal crops.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/masterswitch-for-herbicide-resistance.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)2.30 EUR27.78%
  • SAREUM HOLDINGS (UK)0.76 GBP26.67%
  • PROTHENA PLC (IE)55.46 USD7.46%

FLOP

  • RENEURON (UK)3.00 GBP-4.46%
  • PHARMING (NL)0.24 EUR-4.00%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)55.46 USD50.9%
  • VERNALIS (UK)44.00 GBP34.4%

FLOP

  • SANTHERA (CH)55.30 CHF-26.4%
  • MOLOGEN (D)2.30 EUR-22.0%
  • NICOX (F)10.85 EUR-11.4%

TOP

  • KARO BIO (S)30.80 SEK1849.4%
  • NICOX (F)10.85 EUR474.1%
  • SAREUM HOLDINGS (UK)0.76 GBP230.4%

FLOP

  • BB BIOTECH (D)45.30 EUR-84.6%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.9%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 28.07.2016